PRMT5支持套细胞淋巴瘤的多条致癌通路
套细胞淋巴瘤(MCL)预后差且对靶向治疗耐药后缺乏持久方案。研究采用体外与体内MCL模型的整合转录组学,发现选择性PRMT5小分子抑制剂PRT-382可导致生长停滞和细胞死亡,并在患者来源异种移植中产生治疗获益;MTAP/CDKN2A缺失和野生型TP53被确定为预测有利反应的生物标志物。
要点
- PRMT5在MCL中过表达,通过表观遗传和翻译后修饰调控细胞周期、DNA修复、促生存通路和RNA剪接。
- PRT-382抑制PRMT5后恢复p-RB/E2F调控、诱导p53依赖及非依赖的凋亡,并上调PHLDA3、PTPROt和PIK3IP1。
- MTAP/CDKN2A缺失和野生型TP53被确定为预测有利反应的生物标志物。
核心结论
- 选择性靶向PRMT5在MCL临床前模型中具有显著活性,作者提出对复发/难治性MCL患者进行PRMT5药理学抑制,并认为需在临床试验中进一步研究。
研究设计与样本
- 研究采用体外和体内MCL模型的整合转录组学,评估PRMT5抑制的抗肿瘤活性。
主要发现
- PRT-382处理导致生长停滞和细胞死亡,并在患者来源的MCL异种移植中提供治疗获益。
- PRMT5抑制后的转录重编程恢复细胞周期(p-RB/E2F)调控活性、凋亡性细胞死亡(p53依赖/p53非依赖),并激活B细胞受体-PI3K/AKT信号负调控因子(PHLDA3、PTPROt和PIK3IP1)。
- MTAP/CDKN2A缺失和野生型TP53被确定为预测有利反应的生物标志物。
关键数值与推荐
- PRT-382为选择性小分子PRMT5抑制剂。
- 预测有利反应的生物标志物为MTAP/CDKN2A缺失和野生型TP53。
临床怎么用
- 作者提出对复发/难治性MCL患者进行PRMT5药理学抑制,并认为需在临床试验中进一步研究。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mantle cell lymphoma (MCL) is an incurable B-cell malignancy with an overall poor prognosis, particularly for patients that progress on targeted therapies. Novel, more durable treatment options are needed for patients with MCL. Protein arginine methyltransferase 5 (PRMT5) is overexpressed in MCL and plays an important oncogenic role in this disease via epigenetic and posttranslational modification of cell cycle regulators, DNA repair genes, components of prosurvival pathways, and RNA splicing regulators. The mechanism of targeting PRMT5 in MCL remains incompletely characterized. Here, we report on the antitumor activity of PRMT5 inhibition in MCL using integrated transcriptomics of in vitro and in vivo models of MCL. Treatment with a selective small-molecule inhibitor of PRMT5, PRT-382, led to growth arrest and cell death and provided a therapeutic benefit in xenografts derived from patients with MCL. Transcriptional reprograming upon PRMT5 inhibition led to restored regulatory activity of the cell cycle (p-RB/E2F), apoptotic cell death (p53-dependent/p53-independent), and activation of negative regulators of B-cell receptor-PI3K/AKT signaling (PHLDA3, PTPROt, and PIK3IP1). We propose pharmacologic inhibition of PRMT5 for patients with relapsed/refractory MCL and identify MTAP/CDKN2A deletion and wild-type TP53 as biomarkers that predict a favorable response. Selective targeting of PRMT5 has significant activity in preclinical models of MCL and warrants further investigation in clinical trials.
引用
- Sloan SL, Brown F, Long M, et al. PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma. Blood. 2023. PMID: 37267517. doi:10.1182/blood.2022019419
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。